An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study).
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms APEC
- Sponsors Merck KGaA
- 05 Jun 2018 Results (n=167) of subgroup analysis assessing the impact of tumor side in the APEC study population with RAS wt mCRC presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 20 Jan 2018 Results of subgroup analysis assessing impact of tumor side, presented at the 2018 Gastrointestinal Cancers Symposium.
- 05 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.